A decreased levels of KEAP1 protein were firstly reported to be linked to poor outcome in NSCLC patients treated with platinum-based neoadjuvant regimen and in the NSCLC group of patients with lymph node metastases [8, 9]. This evidence concerns the gene KEAP1 and non-small cell lung carcinoma.